Drug intelligence / Profile preview

investigational Tdap vaccine formulation A

Development stage: Preclinical
Lead developer: Sanofi Pasteur
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

Investigational Tdap vaccine formulation A is a Tetanus Toxoid, reduced Diphtheria Toxoid, and Acellular Pertussis Adsorbed (Tdap) vaccine developed by Sanofi Pasteur. It is administered as a suspension for intramuscular injection and is being studied for its safety profile and ability to elicit humoral and cell-mediated immune responses in young adults. The vaccine aims to provide active immunization against Tetanus, Diphtheria, and Pertussis.

Other names: Tdap vaccine formulation A

Targets

FIM2/FIM3 (Fimbriae types 2 and 3)TT (Tetanus toxoid)

Beyond the preview

Go deeper on investigational Tdap vaccine formulation A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on investigational Tdap vaccine formulation A.

Explore the full profile